

03 Mar 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: optimistic outlook for biopharma IPOs; Boehringer's promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China's HPV vaccine market.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 1 March 2024, including: optimistic outlook for biopharma IPOs; Boehringer's promising MASH results; Viking emerges as obesity contender; Incyte looks to portfolio diversification; and a look at China's HPV vaccine market.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Optimistic IPO Outlook For Biopharma Fueled By Early Trends](#)" - Scrip, 28 Feb, 2024.)

(Also see "[Best-In-Class In MASH? Boehringer's Hopes Raised By Glucagon/GLP-1 Phase II Results](#)" - Scrip, 26 Feb, 2024.)

(Also see "[Viking Emerges As Obesity Contender With Strong Phase II Readout](#)" - Scrip, 27 Feb, 2024.)

(Also see "[Incyte Enters A Data-Rich Year On Path To Portfolio Diversification](#)" - Scrip, 27 Feb,

2024.)

(Also see "[*China HPV Demand Shaping Merck But Competitors Catching Up*](#)" - Scrip, 28 Feb, 2024.)

[*Click here to explore this interactive content online*](#) ✎